Find comprehensive information on Neurofibroma diagnosis, including clinical documentation, ICD-10 codes (D36.1, C72.3), SNOMED CT concepts, and medical coding guidelines. Learn about Neurofibroma symptoms, treatment options, and differential diagnosis for accurate healthcare record keeping and billing. This resource covers Neurofibromatosis type 1 (NF1), schwannomatosis, and plexiform neurofibroma for complete clinical understanding and proper medical documentation.
Also known as
Neurilemoma
Benign tumor of peripheral nerves.
Neurofibromatosis type 1
Genetic disorder causing multiple neurofibromas.
Neurofibromatosis type 2
Genetic disorder with bilateral acoustic neuromas.
Neoplasm of uncertain behavior of peripheral nerves and autonomic nervous system
Tumor of peripheral nerves with unknown potential.
When to use each related code
| Description |
|---|
| Benign nerve tumor |
| Neurofibromatosis type 1 |
| Schwannoma (neurilemmoma) |
Using non-specific neurofibroma codes (e.g., D48.9) instead of specific location/type (e.g., D48.4, D48.5) impacting reimbursement and data accuracy.
Missing or incorrect laterality coding (left/right/bilateral) for neurofibromas, leading to inaccurate reporting and potential claim denials.
Failing to accurately differentiate plexiform neurofibromas (Q85.0) from other types, crucial for NF1 diagnosis and treatment planning.
Patient presents with concerns regarding neurofibroma symptoms and potential neurofibromatosis type 1 (NF1). Clinical evaluation reveals multiple cafe-au-lait macules greater than 5 mm in diameter, consistent with NF1 diagnostic criteria. Patient also exhibits two or more neurofibromas, presenting as soft, fleshy growths on the skin. These cutaneous neurofibromas vary in size and are non-tender to palpation. No evidence of plexiform neurofibromas or optic gliomas was observed during this examination. Patient denies pain, paresthesia, or motor weakness associated with the neurofibromas. Family history is significant for NF1 in the patient's mother. Differential diagnosis includes other neurocutaneous syndromes, such as tuberous sclerosis and schwannomatosis. Assessment supports a clinical diagnosis of neurofibromas, likely associated with NF1. Genetic testing is recommended to confirm the diagnosis of NF1. The patient was counseled on the natural history of neurofibromas and NF1, including the potential for complications such as optic pathway gliomas, spinal neurofibromas, and malignant peripheral nerve sheath tumors. Treatment plan includes regular monitoring of neurofibroma growth and development, with surgical excision considered for symptomatic or rapidly growing lesions. Patient education regarding neurofibroma symptoms, genetic counseling, and surveillance recommendations was provided. ICD-10 code Q85.0 for neurofibromatosis type 1 and CPT code 99214 for established patient office visit were assigned. Follow-up appointment scheduled in six months for continued surveillance.